CIRM Funded Clinical Trials

A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients with Mucopolysaccharidosis Type 1

Disease Area:

Bone or Cartilage Disease, Hearing Loss, Intellectual Disability, Metabolic Disorders, Vision Loss

Investigator:

Institution:

CIRM Grant:

Award Value:

$8,000,000.00

Trial Sponsor:

Immusoft Corporation

Trial Stage:

Phase 1

Trial Status:

Launching

Targeted Enrollment:

N/A